Development of a Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease Prediction in UK Biobank
Genes · 2024
DOI: 10.3390/genes16010033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Panagiota Giardoglou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, 17671 Athens, Greece. Hauptthemen laut MEDLINE: Multifactorial Inheritance, Non-alcoholic Fatty Liver Disease, Fatty Liver. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Secretariat for Research and Innovation, EU and Greek national funds.
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of liver-related morbidity and mortality. Although the invasive liver biopsy remains the golden standard for MASLD diagnosis, Magnetic Resonance Imaging-derived Proton Density Fat Fraction (MRI-PDFF) is an accurate, non-invasive method for the assessment of treatment response. This study aimed at developing a Polygenic Risk Score (PRS) to improve MRI-PDFF prediction using UK Biobank data to assess an individual’s genetic liability to MASLD.
Methods
We iteratively sequestered 10% of MRI-PDFF samples as a validation set and split the rest of each dataset into base and target partitions, containing GWAS summary statistics and raw genotype data, respectively. PRSice2 was deployed to derive PRS candidates. Based on the frequency of SNP appearances along the PRS candidates, we generated different SNP sets according to variable frequency cutoffs. By applying the PRSs to the validation set, we identified the optimal SNP set, which was then applied to a Greek nonalcoholic fatty liver disease (NAFLD) study.
Results
Data from 3553 UK Biobank participants yielded 49 different SNP sets. After calculating the PRS on the validation set for every SNP set, an optimal PRS with 75 SNPs was selected (incremental R2 = 0.025, p-value = 0.00145). Interestingly, 43 SNPs were successfully mapped to MASLD-related known genes. The selected PRS could predict traits, like LDL cholesterol and diastolic blood pressure in the UK Biobank, as also disease outcome in the Greek NAFLD study.
Conclusions
Our findings provide strong evidence that PRS is a powerful prediction model for MASLD, while it can also be applied on populations of different ethnicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, 17671 Athens, Greece.
- Department of Nutrition and Dietetics, School of Physical Education, Sport Science and Dietetics, University of Thessaly, 42132 Trikala, Greece.
- Institute for Fundamental Biomedical Research, Biomedical Sciences Research Center 'Alexander Fleming', 16672 Vari, Greece.
ORCID-Profile: Ioanna Gavra, Athina I Amanatidou, Ioanna Panagiota Kalafati, Panagiotis Symianakis, Maria Kafyra, Panagiotis Moulos, George V Dedoussis
Förderung
- General Secretariat for Research and Innovation
- EU and Greek national funds
Zitieren
APA
Giardoglou, P., Gavra, I., Amanatidou, A. I., Kalafati, I. P., Symianakis, P., Kafyra, M., Moulos, P., & Dedoussis, G. V. (2024). Development of a Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease Prediction in UK Biobank. Genes. https://doi.org/10.3390/genes16010033
Vancouver
Giardoglou P, Gavra I, Amanatidou AI, Kalafati IP, Symianakis P, Kafyra M, et al. Development of a Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease Prediction in UK Biobank. Genes. 2024. doi:10.3390/genes16010033
BibTeX
@article{Giardoglou2024,
author = {Giardoglou, Panagiota and Gavra, Ioanna and Amanatidou, Athina I and Kalafati, Ioanna Panagiota and Symianakis, Panagiotis and Kafyra, Maria and Moulos, Panagiotis and Dedoussis, George V},
title = {Development of a Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease Prediction in UK Biobank},
journal = {Genes},
year = {2024},
doi = {10.3390/genes16010033}
}
EUVIMED